The Challenge of Making Benefit-Sharing Real
The Nagoya Protocol's requirement for "fair and equitable" benefit-sharing is clear in principle. In practice, translating that principle into contractual reality requires negotiation of specific percentages, payment structures, non-monetary components, timing triggers, and enforcement mechanisms - a complex process that many provider country governments and commercial users find difficult to navigate. The result, too often, is either no agreement (blocking legitimate research access) or agreements whose terms are so loosely specified that they are unenforceable in practice.
The historical record of ABS agreements - limited as it is by the confidentiality of most commercial MAT negotiations - provides guidance on what has worked. Below, we examine a selection of documented precedents before explaining how IsoGentiX's benefit-sharing framework is calibrated against them.
Documented Precedents
India and the Kani Tribe: A Community-Level Success
The Jeevani case in India represents one of the most frequently cited positive examples of ABS benefit-sharing at the community level. The Kani tribal community of Kerala shared traditional knowledge about the aromatic medicinal plant Trichopus zeylanicus with the Tropical Botanical Garden and Research Institute (TBGRI), which developed a commercial preparation marketed as Jeevani. A benefit-sharing arrangement was negotiated in which the Kani community received fifty per cent of the royalties paid by the commercial licensee and fifty per cent of the licence fee paid to TBGRI [1].
While the absolute amounts were modest relative to what a blockbuster pharmaceutical would generate, the structural principle - community-level benefit-sharing linked directly to commercial revenues - was regarded as a model by the CBD Secretariat. The Kani case demonstrated that meaningful community benefit-sharing is operationally achievable, not merely an aspirational commitment.
Brazil: Standardising the Floor
Brazil's evolution of its ABS framework illustrates a different approach: moving from case-by-case negotiation to a statutory minimum floor. Under Brazil's 2015 Biodiversity Law and its 2018 implementing decree, companies accessing Brazilian genetic resources or traditional knowledge for commercial purposes are required to pay a minimum of one per cent of net annual revenues from the commercialised product to a National Benefit-Sharing Fund [2].
The rationale was explicit: a standard floor eliminates the transaction costs of prolonged negotiation for smaller companies and researchers, reduces the uncertainty that had been deterring legitimate access applications, and guarantees that the national fund receives a defined minimum regardless of the negotiating capacity of individual communities or government departments. The Brazilian model has attracted both admiration and criticism - critics argue that one per cent is too low relative to the commercial value generated; proponents argue that a reliable, enforceable minimum is more valuable in practice than a theoretically higher but operationally contested rate [3].
The INBio-Merck Agreement: First-Generation ABS
The 1991 agreement between Costa Rica's National Biodiversity Institute (INBio) and Merck Sharp & Dohme is among the earliest examples of a structured bioprospecting arrangement and remains a reference point for subsequent frameworks. Merck provided INBio with an upfront payment of $1.1 million in exchange for access to biological specimens and the right to screen extracts for pharmaceutical activity, with a commitment to royalty payments on any commercially developed product and a contribution to Costa Rica's national park system [4].
No commercial drug was ultimately developed from the programme, making royalty payments moot, but the model demonstrated that structured access-and-benefit agreements could be negotiated in practice and executed in good faith by commercial actors. The INBio-Merck precedent shaped the thinking of every ABS framework that followed it.
The Cali Fund and Digital Sequence Information
A rapidly evolving area of ABS policy concerns Digital Sequence Information (DSI) - genomic and metabolomic data in digital form, as distinct from physical biological material. The CBD's 2022 Kunming-Montreal Global Biodiversity Framework and the subsequent Cali Fund mechanism, operationalised through 2024 CBD decisions, established for the first time a multilateral benefit-sharing mechanism for commercial use of DSI from the Convention's genetic resource pool [5].
This is directly relevant to companies like IsoGentiX whose primary commercial product is data rather than physical specimens. IsoGentiX's compliance architecture explicitly provides for contributions to the Cali Fund as a component of benefit-sharing distributions - ensuring that obligations under the emerging DSI framework are met automatically, without requiring specific negotiation in each MAT.
IsoGentiX's Benefit-Sharing Framework
IsoGentiX's benefit-sharing architecture is designed to be automatic, transparent, auditable, and decoupled from company discretion. The specific monetary benefit-sharing rate for each collection region will be negotiated with Madagascar's MEDD through the MAT process, calibrated against the documented international precedents above. The framework is structured around four recipient categories:
Community Trust Funds - representing local communities in each collection region, receiving the largest share of the benefit-sharing pool, distributed quarterly via mobile-money APIs directly to community trust accounts.
National ABS Fund (MEDD/MinEnv) - representing Madagascar's sovereign interest in its genetic resources, receiving a defined share of the benefit-sharing pool via government digital payment systems.
Cali Fund (CBD DSI Mechanism) - reflecting IsoGentiX's obligations under the international DSI benefit-sharing framework, with contributions registered with the CBD.
IsoGentiX Treasury - the balance of commercial revenues after benefit-sharing obligations are met, funding platform operations, scientific programme, and returns to investors.
Non-monetary benefits are an integral component of IsoGentiX's commitment to Madagascar, not an afterthought. The IsoGentiX Institute (IGI) operates as a permanent in-country sequencing and analysis facility with a majority-Malagasy workforce. Technology transfer in genome sequencing and bioinformatics, co-authorship opportunities for Malagasy scientists, and priority employment of local staff create durable scientific capacity independent of any particular commercial outcome [6].
Automation as a Guarantee of Integrity
A recurring challenge in benefit-sharing implementation is the gap between contractual obligation and actual payment. Communities and governments that have entered into MAT agreements on paper often find that payments are delayed, disputed, or simply fail to materialise. IsoGentiX's smart-contract architecture is specifically designed to close this gap: quarterly distributions execute automatically upon revenue receipt, without requiring any action from beneficiary communities or government departments [7].
The distribution is on-chain, publicly verifiable in aggregate, and annually audited by an independent auditor whose report is shared with MEDD, investors, and communities. This is not optional transparency - it is a structural feature of the system, embedded from the outset.